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Abstract
Introduction
The majority of newly diagnosed chronic lymphocytic leukemia (CLL) patients are followed
initially by watch and wait (WAW). Clinical practice varies and the value of frequent follow-
up visits remains unclear. Thus, in this study we investigated the clinical value of follow-up
visits for patients with CLL.
Methods
We collected data from diagnosis and follow-up visits for patients diagnosed with CLL and
managed by WAW in the North Denmark Region between 2007–2014. High- and low-risk
group patients were determined by Binet stage, IgVH status, and cytogenetics at diagnosis.
The effect of risk group allocation on the probability of receiving CLL-directed treatment
within two years was included in a multivariable logistic regression model adjusted for age
and blood test results.
Results
273 patients were included in the study with a median follow-up of 3 years (IQR: 1.6–5.4).
Overall, the median interval between follow-up visits was 98 days (95% CI: 96–100) (high-
risk patients: 91 days [95% CI: 86–95] vs. low-risk patients: 105 days [95% CI: 100–110]).
Among 2,312 follow-up visits, only 387 (17%) were associated with interventions. At the fol-
lowing time points: 6 months, 1 year, and 1.5 years, patients with low-risk CLL had signifi-
cantly lower odds of initiating treatment compared to patients with high-risk CLL.
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Conclusion
WAW plays an important role in managing CLL. Interventions at follow-up visits were infrequent
and low-risk patients had significantly lower risk of treatment initiation. We question the value of
routine follow-up in CLL in the absence of changes in symptoms and/or blood test results.
Introduction
Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world
and often characterized by an indolent clinical course [1]. More than 80% of patients are inci-
dentally diagnosed by routine blood tests, and the majority present with early-stage disease
upon diagnosis [2, 3]. Upfront treatment is not associated with better outcome for patients
with asymptomatic, early-stage CLL and therefore, watch and wait (WAW) is a widely
accepted initial management strategy [4–6].
A substantial fraction of CLL patients (up to 40%) managed by WAW will not require CLL-
directed treatment during their lifetime [7]. Risk stratification using clinical staging, cytogenet-
ics, and immunoglobulin heavy chain gene mutational (IgVH) status can identify patient sub-
groups at greater risk of developing symptomatic disease [7, 8]. Still, considerable
heterogeneity within identified risk groups exists and many patients are offered lifelong fol-
low-up in specialized hematology/oncology clinics.
The value of routine follow-up in CLL, however, is largely unknown, and local practice var-
ies, as evidence-based follow-up guidelines do not exist.
Due to the ageing populations in the Western world and greater awareness of early signs of
CLL, the number of CLL patients that will be managed by WAW is likely to increase over the
coming years [7]. Therefore, studies that explore the value of multiple routine follow-ups in
CLL are important, not only from a patient perspective, but also to ensure sustainable clinical
practice in future health care. In the present study, we examined the findings and outcomes of
routine follow-up visits for CLL.
Methods
Study cohort
Patients diagnosed with CLL in the North Denmark Region were identified using the local reg-
istrations in the Danish National Chronic Lymphocytic Leukemia Registry [9]. All patients
who underwent diagnostic workup in the period May 2007–December 2014 and follow-up at
the Department of Hematology at Aalborg University Hospital were screened for eligibility.
Inclusion criterion for this retrospective study was initial management by WAW that lasted
for at least 90 days. This study was approved by the Danish Data Protection Agency (ID: 2015–
129) and the head of the Department of Hematology at Aalborg University Hospital. All analy-
ses were performed on anonymized data.
Data collection and variables
Baseline clinicopathologic characteristics were obtained from the local CLL Registry and
health records. Follow-up visits were defined as any outpatient hospital visit to the Department
of Hematology between diagnosis and initiation of CLL-directed treatment. Information from
each visit were collected and included clinical findings (symptoms and physical examination),
laboratory findings, and interventions.
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Recorded symptoms included fatigue, weight loss, night sweats, subfebrilia/febrilia, infec-
tion tendency, bleeding tendency, and/or other possible CLL-related symptoms, such as loss of
appetite, pain/fullness in the stomach, or anemia-related symptoms. Physical examination
findings included lymph node or organ (spleen and liver) enlargement.
Laboratory results included hemoglobin levels, thrombocyte counts, leukocyte counts, and
lactate dehydrogenase (LDH) levels. Leukocyte count was used as a surrogate for lymphocyte
count, as leukocyte differential count was not routinely measured. Cut-offs for abnormal
blood test results were defined to reflect considerable deviations of blood levels relevant for
CLL: Hemoglobin < 6.2 mmol/L (< 10.0 g/dL)[10], thrombocytes < 100 x 109/L (< 100,000/
mm3) [10], leukocytes� 30x109/L (> 3,000/mm3) [11], and LDH� 205 U/L for patients < 70
years and� 255 U/L for patients� 70 years. Presence of one or more of these values was
defined as having abnormal blood test results.
An intervention at a follow-up visit was defined as follows: referral for medical imaging (X-
ray, ultrasound, or CT-scan), ordering of biopsy (lymph node or bone marrow), request for
additional/increased frequency of blood tests and/or follow-up visits, or treatment for CLL-
complications (corticoid steroids for immunological complications such as hemolysis, blood
transfusion, erythropoietin, or immunoglobulin substitution) during the follow-up period.
Patients were followed until they were started on CLL-directed treatment, discharged to
primary care, death, whichever occurred first, or censored at December 31st, 2015.
Each patient was allocated to either a high- or low-risk CLL group. High-risk CLL was
defined by the presence of one or more of the following risk factors: Binet B/C, 11q-/17p-, and/
or unmutated IgVH, whereas low-risk CLL was defined by the absence of all of these clinico-
pathologic features (i.e. Binet A, no aberrations and/or 13q- and/or Tri12, and mutated IgVH).
Statistical analysis
Blood values were analyzed as continuous variables, while all other variables were categorical.
Baseline characteristics were reported using median or mean for continuous variables and fre-
quencies for categorical variables. Information on symptoms was available for all visits, while
information about physical examinations was available from 79% of the visits. Blood tests were
taken before 99% of visits.
The median follow-up time was estimated by reversing the role of events and censoring in
the Kaplan-Meier estimator (the reverse Kaplan-Meier method) [12]. Time to first treatment
was defined as the time from diagnosis to initiation of CLL-directed treatment and the cumu-
lative incidence of initiating treatment was calculated by considering death as a competing
risk.
Multivariable logistic regression models were used to inspect the effect of risk group alloca-
tion on the probability of receiving CLL-directed treatment within two years. Three different
models, all adjusted for age and blood test results, were fitted and obtained by considering
patients at risk, i.e. those who were not censored, alive, and had not yet received treatment, at
the following time points: 6 months, 1 year, and 1.5 years post-diagnosis. The outcome variable
in the logistic regression model was receiving treatment within two years after the given time
points. The treatment status two years after the time point was missing for patients who experi-
enced a competing risk, i.e. death, or were censored at that time. To account for the censoring
and the competing risk, pseudo-values representing the probability that a subject received
treatment within two years were used as the outcome in the multivariable logistic regression
models [13]. Blood test results were collected in relation to the most recent follow-up visit
before the three given time points (S1 Fig). The respective blood test values and age were
rescaled so that, at baseline, their standard deviation equaled one
Limited value of watch and wait in CLL
PLOS ONE | https://doi.org/10.1371/journal.pone.0208180 December 27, 2018 3 / 11
Median time between visits was calculated using the non-parametric Wang-Chang estima-
tor and confidence intervals were obtained by bootstrapping [13, 14].
The effect of the clinical and laboratory findings on interventions was inspected using an
Andersen-Gill model of the intensity, i.e. the event rate at a given time given the information
available at that time, in which the findings were included as time-varying covariates, while
standard errors were obtained using a robust jackknife estimator [15]. All statistical analyses
were carried out using R version 3.4.1 (S1 Appendix).
Results
Study cohort
A total of 305 patients with newly diagnosed CLL were identified during the surveyed period
(2007–2014). 32 patients were excluded due to treatment-initiation within 90 days of diagno-
sis, which left a total of 273 (90%) patients, initially managed by WAW, for further analyses
(Table 1). Median age at diagnosis was 71 years and approximately 60% of patients were male.
The cohort consisted of 66% patients with low-risk CLL and 34% with high-risk CLL.
Characterization of follow-up period
The median follow-up time was 3 years (IQR: 1.6–5.4), and 2,312 follow-up visits were con-
ducted during the study period, with median interval between visits being 98 days (95% CI:
96–100) (high-risk patients: 91 days [95% CI: 86–95] vs. low-risk patients: 105 days [95% CI:
100–110]). Within the first 2 years after diagnosis, the median time between visits was 98 days
(95% CI: 98–98) (high-risk patients: 91 days [95% CI: 87–94] vs. low-risk patients 99 [95% CI:
92–103]). During the period starting from 2 years post-diagnosis the median time between vis-
its was 182 days (95% CI: 170–195) (high-risk group: 126 [95% CI: 100–158] vs. low-risk
group: 190 [95% CI: 185–196]).
By the end of the study, 126 patients (46%) remained on WAW at the hospital, 44 patients
(16%) were discharged to primary care management due to stable disease and/or patient pref-
erences, 76 patients (28%) had received CLL-directed treatment due to disease progression,
and 27 patients (10%) had died (all-cause mortality) before initiation of CLL-directed treat-
ment. Overall, 63 patients (23%) died during the study period.
Risk group and initiation of CLL-directed treatment
The risk of initiating CLL-directed treatment within 5 years of diagnosis was 36% (95% CI:
29–44), with high-risk patients showing greater risk (70%, [95% CI: 56–84]), compared to low-
risk patients (19%, [95% CI: 12–26], Fig 1).
Next, we investigated the effect of risk group on the 2-year odds of treatment initiation
from the three selected time-points (6 months, 1 year, and 1.5 years). Odds ratios and 95%
confidence intervals of the logistic regression models are shown in Fig 2. At each of the three
selected time-points, the low-risk group was associated with decreased odds of 2-year treat-
ment initiation compared to the high-risk group. Additionally, thrombocyte and leukocyte
counts were, as expected, significantly associated with odds of 2-year treatment initiation at all
three time points. Hemoglobin was significantly associated with odds of 2-year treatment initi-
ation at 6 months and 1 year.
Outcome of follow-up visits
Within the study period, 576 interventions occurred at 387 follow-up visits (17% of all visits).
The probability of undergoing at least one intervention within 5 years of diagnosis was 74%
Limited value of watch and wait in CLL
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Table 1. Baseline characteristics of the study participants.
Age–yr
Median (range) 71 (33–98)
Sex–n (%)
Male 164 (60.1)
Hemoglobin < 6.2 mmol/L–n (%)
10 (3.7)
Thrombocytes <100 x 109/L–n (%)
4 (1.5)
Leukocyte count�30 x 109/L–n (%)
70 (25.6)
LDH� 205 U/L for patients <70 years and � 255 U/L for patients�70 years–n (%)
39 (14.3)
Beta2-microglobulin >340 nmol–n (%)
Yes 21 (7.7)
No 172 (63.0)
Unknown 80 (29.3)
Binet stage–n (%)
A 240 (87.9)
B 30 (11.0)
C 3 (1.1)
IgVH status–n (%)
Mutated IgVH 96 (35.2)
Unmutated IgVH 66 (24.2)
Unknown 111 (40.7)
Cytogenetic status–n (%)
Normal 101 (37.0)
Aberrations 147 (53.8)
Del 13q14 120
Trisomy 12 33
Del 11q 14
Del17p 3
Unknown 25 (9.2)
CD38 –n (%)
Yes 68 (24.9)
No 174 (63.7)
Unknown 31 (11.4)
Performance status–n (%)
0 213 (78.0)
1 46 (16.9)
2 9 (3.3)
3 1 (0.4)
4 3 (1.1)
Unknown 1 (0.4)
Risk group–n (%)
Low 181 (66.3)
High 92 (33.7)
https://doi.org/10.1371/journal.pone.0208180.t001
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(95% CI: 67–81). Analyzing time from diagnosis to first intervention, we found that 39% of
patients had a first intervention during the first year of follow-up, 16% during the second year,
7% during the third year, and 16% between the fourth and sixth year after diagnosis.
Common interventions were increase in the frequency of follow-up visits (207 [9% of all fol-
low-up visits]), increase in the frequency of blood tests (124 [5% of all follow-up visits]), addi-
tional blood tests (77 [3% of all follow-up visits]) and imaging (76 [3% of all follow-up visits])
(S1 Table).
Interventions at follow-up visits (387) were most frequently associated with the following
constellations of clinical and laboratory findings: symptoms and/or physical findings and abnor-
mal blood test results (210 [54%]), abnormal test results alone (87 [22%]), and symptoms and/or
physical findings (54 [14%]), as shown in Table 2 (see S2 Table for the association between
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Fig 1. Cumulative incidence of the probability of initiating treatment. Cumulative incidence curves showing the probability of initiating
treatment for low-risk patients (green) and high-risk patients (red).
https://doi.org/10.1371/journal.pone.0208180.g001
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specific clinical and laboratory findings and interventions at follow-up visits). Altogether,
abnormal blood test results were present at 297 (77%) follow-ups with interventions along
with 69 (91%) cases of treatment initiations. Physical examination alone was related to 15 (4%)
visits with interventions (in total physical examination alone was the reason for intervention
in 0.6% of all visits (2312)) and was never the only documented reason for treatment initiation.
The importance of symptoms and/or physical findings and abnormal blood test results (HR 9.8
[95% CI: 6.9–13.8]) as compared to symptoms and/or physical findings (HR 3.6 [2.4–5.4]) as
well as abnormal blood test results alone (HR 3.1 [2.2–4.6]) was confirmed by their larger HR
estimates.
Decreasing 
hemoglobin level
Increasing 
LDH level
Increasing 
leukocyte count
Decreasing 
thrombocyte count
Age
Risk group: low
3210
Odds ratio (95% CI)
Alive at
6 months
1 year
1.5 year
Fig 2. Odds ratio of 2-year predicted treatment initiation. Odds ratio for 2-year treatment initiation for patients at risk, estimated at the time points 6 months, 1
year, and 1.5 years post-diagnosis. The standardized thrombocyte count and hemoglobin level were multiplied by minus one in order to make the odds ratios
correspond to a decrease in these counts.
https://doi.org/10.1371/journal.pone.0208180.g002
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Discussion
This study examined the outcome of routine follow-up in CLL. Overall, we observed infre-
quent occurrence of interventions at follow-up visits. Furthermore, risk group allocation was
significantly associated with 2-year odds of treatment during the first 1.5 years after diagnosis.
Prognostic modeling increasingly involves the use of genetic markers [8, 16]. This is useful
for baseline risk stratification of newly diagnosed patients, as full information is available at
that time. However, some patients with low-risk disease require treatment after a short WAW
period and not all patients with high-risk CLL experience early progressions. Therefore, dis-
ease surveillance is commonly offered to all patients regardless of baseline risk stratification.
Disease surveillance during WAW still relies on simple clinical and laboratory findings. The
main purpose is to detect disease progression that requires interventions in the form of addi-
tional visits or tests, or initiation of CLL-directed treatment. Considering this, we decided to
investigate whether clinical and laboratory findings could provide valuable information during
WAW follow-up.
In the analyzed patient cohort, hemoglobin < 6.2 mmol/L and thrombocytes < 100 x 109/L
were rare finding during follow-up, which was expected both represent thresholds commonly
used for treatment initiation [6].
The majority of CLL patients are managed by WAW for long periods of time and surveil-
lance of a cancer disease without undergoing treatment can be a source of profound emotional
distress and anxiety. Especially, emotional quality of life has been shown to be markedly
impacted in CLL at all stages [17]. Moreover, emotional and social quality of life as well as lev-
els of depression and anxiety are all very similar between CLL patients managed by WAW and
those undergoing active CLL-directed treatment [18]. With this in mind, it would be valuable
to obtain more dynamic estimations of disease progression risk during WAW to help reassure
patients and potentially reduce worry and anxiety [7].
This study showed that both high- and low-risk CLL patients were followed closely during
the follow-up period, with no significant difference between groups within the first two years
(3.7 follow-up visits per year). Limited evidence exists on the frequency of follow-up during
WAW. Shanafelt et al. have suggested the use of an individualized follow-up approach for Rai
stage 0/Binet stage A, using molecular markers to stratify patients into risk groups [19]. Eich-
horst et al. have suggested follow-up visits for early stage asymptomatic patients every 3–12
months [20], whereas Oscier et al. recommended WAW follow-up visits at least twice within
Table 2. Association between clinical and laboratory findings and outcome of follow-up visits.
Number of follow-up visits with
interventions
Intensity of
intervention*
Number of follow-up visits with the decision to
initiate CLL-directed treatment
Frequency
n (%)
HR (95% CI) Frequency
n (%)
Symptoms and/or physical findings 54 (13.9) 3.6 (2.4–5.4) 5 (6.6)
Abnormal blood test results�� 87 (22.5) 3.1 (2.2–4.6) 14 (18.4)
Symptoms and/or
Physical findings and Abnormal
blood test results
210 (54.3) 9.8 (6.9–13.8) 55 (72.4)
Uncertain 36 (9.3) 1 (REF) 2 (2.6)
Total 387 (100) 76 (100)
�Hazard ratios (HR) of an Andersen-Gill (AG) model for the intensity of the interventions with clinical and laboratory findings as time-varying covariates are reported.
��Hemoglobin < 6.2 mmol/L (< 10.0 g/dL)[10], thrombocytes < 100 x 109/L (< 100,000/mm3) [10], leukocytes �30x109/L (> 3,000/mm3) [11], and LDH�205 U/L
for patients <70 years, or�255 U/L for patients�70 years.
https://doi.org/10.1371/journal.pone.0208180.t002
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the first year of diagnosis, and once per year after that [2]. Compared to these recommenda-
tions, low-risk patients in our cohort were seen twice yearly after two years of follow-up,
which however was significantly less frequent compared to high-risk patients (seen roughly 3
times a year). Despite frequent follow-up visits in our study, the majority of visits (83%) did
not result in any interventions and it is likely that more individualized follow-up schedules
based on dynamic risk estimations could reduce the relatively high frequency of visits, without
compromising timely intervention. The CLL International Prognostic Index (CLL-IPI) repre-
sents a novel and readily implementable tool to achieve more individualized WAW follow-up
[8]. This prognostic score can identify four prognostic subgroups and although originally gen-
erated to predict overall survival, the index has been validated to predict time to first treatment
in early stage CLL [21]. The most recent Danish CLL guidelines propose that the CLL-IPI
should partially replace the current risk stratification used in this study, and thus future evalua-
tion may prove the CLL-IPI a refined approach to more effectively risk stratify the large group
of patients with early stage CLL [22].
Blood test results could further pave the way for more dynamic risk estimations to assess
the need for follow-up visits at a given time. Moreover, visits to the outpatient clinic may in
some cases be replaced by telemedicine if patients have no symptoms and blood tests do not
indicate significant and unexpected disease progression. Telemedicine in cancer follow-up was
reviewed by Dickinson et al. and did not appear to compromise patient satisfaction nor safety
[23]. Moreover, in a pilot study by Overend et al., patients with indolent chronic hematologic
malignancies (40% with CLL) were managed effectively and safely via a Teleclinic and 62% of
patients preferred this over attending traditional outpatient clinics [24]. To that end, it is impor-
tant to evaluate if telemedicine solutions as a replacement of outpatient visits reduce health anx-
iety among CLL patients with indolent disease. Other points to explore, are whether telephone/
video follow-up visits could be nurse-led, potentially leading to a physician-led telephone/video
visit or even a hospital visit in the presence of any concerns or symptoms. More follow-up in
primary care may also be an option for some patients, possibly as a shared care solution.
It is important to note that this study relied on data not obtained for this particular study.
Due to the retrospective nature of this study, it was not possible to assess how various factors
weighed in on the physician’s decision to request interventions and treatment. In addition, by
relying on symptoms/findings noted to clinical files we cannot exclude biased results such as
minor symptoms not reported by the patients or interpreted by the physician.
In summary, WAW remains a cornerstone in managing CLL. We found that the majority
of follow-up visits did not result in any interventions and that low-risk patients had signifi-
cantly lower risk of initiating CLL-directed treatment compared to high-risk group patients.
Furthermore, interventions and treatment initiation were found to be highly associated with
abnormal blood test results and reported symptoms and may guide the need to come to the
outpatient clinic.
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